Table 3

Sensitivity analyses
Endpoint Confidence intervals Prediction intervals Only published data Without STEMI Only combined DEB+BMS Excluding progenitor cell stent DEB exclusively
MACE 0.95 (0.64 to 1.39) 0.95 (0.35 to 2.52) 0.95 (0.64 to 1.39) 0.84 (0.61 to 1.15) 0.84 (0.61 to 1.15) 0.95 (0.64 to 1.39) 1.07 (0.67 to 1.70)
TLR 1.09 (0.71 to 1.68) 1.09 (0.31 to 3.83) 0.97 (0.63 to 1.50) 1.01 (0.68 to 1.51) 1.00 (0.65 to 1.55) 1.20 (0.79 to 1.82) 1.18 (0.70 to 1.99)
Binary restenosis 0.96 (0.48 to 1.93) 0.96 (0.10 to 9.05) 0.96 (0.48 to 1.93) 0.77 (0.40 to 1.48) 0.82 (0.40 to 1.66) 1.18 (0.59 to 2.35) 1.20 (0.48 to 2.96)
MI 1.26 (0.49 to 3.21) 1.26 (0.13 to 11.83) 0.86 (0.40 to 1.85) 1.13 (0.42 to 3.06) 1.18 (0.43 to 3.24) 1.30 (0.46 to 3.65) 1.69 (0.62 to 4.59)
Mortality 0.79 (0.30 to 2.11) NA 0.58 (0.20 to 1.71) 0.78 (0.29 to 2.15) 0.76 (0.27 to 2.18) 0.88 (0.31 to 2.45) 0.93 (0.32 to 2.71)
ST 1.45 (0.42 to 5.01) NA 1.45 (0.42 to 5.01) 1.13 (0.29 to 4.40) 1.50 (0.41 to 5.57) 1.52 (0.41 to 5.63) 1.59 (0.40 to 6.36)

BMS, bare metal stent; DEB, drug eluting balloon; MACE, major adverse cardiac events; MI, myocardial infarction; RR, relative risk (and 95% confidence intervals); ST, stent thrombosis; TLR, target lesion revascularization.

Fröhlich et al.

Fröhlich et al. BMC Medicine 2013 11:123   doi:10.1186/1741-7015-11-123

Open Data